A Prospective Cohort Study of Efficacy, Safety and Characterization of Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients

69HCL17_0769

Hematopoietic stem cell transplantation (HSCT) is a cellular therapy aiming at curing some hematological diseases. Upon transplantation, recipients experience a phase of profound immune suppression with loss of protective immunity against most infectious agents. Revaccination of HSCT recipients against vaccine-preventable infections is an important post-transplant intervention for reducing morbi-mortality. The VaccHemInf project aims at assessing the efficacy of recommended vaccines in adult recipients of HSCT, through the antibody titers reference method and a panel of immune functional assays.

2018-04-27

2021-01-21

2023-01-21

Completed

152

Inclusion Criteria: * allogeneic and autologous HSCT recipients * ≥ 18 year-old * patients having been informed of the conditions of the study (24-month follow-up) and having signed the informed consent form * Person with social security insurance • Additional inclusion criteria for healthy volunteers enrolled (10 volunteers)in the ancillary study of influenza vaccine response: * health-care workers recruited from the hospital staff Exclusion Criteria: * Patient with innate or acquired immune deficiency (severe combined immunodeficiency, Hepatitis C virus (HCV), HBV, HIV infections at any stage) * Pregnant or breastfeeding women * History of previous severe allergic reaction to vaccine components * Patient with no social security coverage, with restricted liberty or under legal protection.

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 152, 'type': 'ACTUAL'}}

2024-03-20